CN104470975B - 可用于治疗诊断学的聚合纳米颗粒 - Google Patents

可用于治疗诊断学的聚合纳米颗粒 Download PDF

Info

Publication number
CN104470975B
CN104470975B CN201380023187.0A CN201380023187A CN104470975B CN 104470975 B CN104470975 B CN 104470975B CN 201380023187 A CN201380023187 A CN 201380023187A CN 104470975 B CN104470975 B CN 104470975B
Authority
CN
China
Prior art keywords
polymer
nano particle
nanoparticles
monomer
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380023187.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104470975A (zh
Inventor
吴晓渔
艾利莱扎·莎尔维利
蔡平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Original Assignee
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto filed Critical University of Toronto
Publication of CN104470975A publication Critical patent/CN104470975A/zh
Application granted granted Critical
Publication of CN104470975B publication Critical patent/CN104470975B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/14—Powdering or granulating by precipitation from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Graft Or Block Polymers (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Immunology (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380023187.0A 2012-03-02 2013-03-04 可用于治疗诊断学的聚合纳米颗粒 Active CN104470975B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605995P 2012-03-02 2012-03-02
US61/605,995 2012-03-02
PCT/CA2013/000203 WO2013127004A1 (en) 2012-03-02 2013-03-04 Polymeric nanoparticles useful in theranostics

Publications (2)

Publication Number Publication Date
CN104470975A CN104470975A (zh) 2015-03-25
CN104470975B true CN104470975B (zh) 2018-02-27

Family

ID=49081494

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380023187.0A Active CN104470975B (zh) 2012-03-02 2013-03-04 可用于治疗诊断学的聚合纳米颗粒

Country Status (7)

Country Link
US (2) US10233277B2 (https=)
EP (1) EP2820070B1 (https=)
JP (1) JP6152391B2 (https=)
CN (1) CN104470975B (https=)
CA (1) CA2865925C (https=)
SG (1) SG11201405407WA (https=)
WO (1) WO2013127004A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015149188A1 (en) 2014-04-03 2015-10-08 The Governing Council Of The University Of Toronto Multifunctional nanoparticle compositions and uses thereof
US20180021265A1 (en) * 2015-02-18 2018-01-25 Memorial Sloan Kettering Cancer Center Compositions and methods for nanoparticle-based drug delivery and imaging
US10695400B2 (en) 2015-08-03 2020-06-30 Enb Therapeutics, Inc. Compositions and methods for treating cancers associated with ETBR activation
CN105732901B (zh) * 2016-04-22 2018-02-02 广西大学 一种木薯渣磁性微球及其制备方法
CN108003286A (zh) * 2017-12-15 2018-05-08 北京思如诺科技有限公司 一种用于肿瘤放射性诊疗的共聚物及其制备方法和应用
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
CN110960508B (zh) * 2019-11-13 2021-11-23 湖北大学 一种具有抗蛋白吸附和靶向能力的淀粉纳米粒子及其制备方法
US20210361570A1 (en) * 2020-05-19 2021-11-25 Mcmaster University In situ gelling polysaccharide-based nanoparticle hydrogel compositions, and methods of use thereof
WO2022024754A1 (ja) * 2020-07-27 2022-02-03 国立大学法人大阪大学 微小粒子の製造方法
WO2024254703A1 (en) * 2023-06-15 2024-12-19 Qurcan Therapeutics Inc. Intelligent polymer-lipid based nano drug delivery system to improve the bbb-penetration by dual active brain targeting strategies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1709935A (zh) * 2005-06-17 2005-12-21 天津大学 淀粉接枝聚丙烯酰胺及其衍生物反相乳液的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57138411A (en) 1981-02-16 1982-08-26 Nippon Denso Co Ltd Air intake controller for car air conditioner
US4690996A (en) 1985-08-28 1987-09-01 National Starch And Chemical Corporation Inverse emulsions
GB9411080D0 (en) 1994-06-02 1994-07-20 Unilever Plc Treatment
JP2002537343A (ja) * 1999-02-23 2002-11-05 アイシス・ファーマシューティカルス・インコーポレーテッド 多重粒子製剤
CN1388169A (zh) 2002-07-26 2003-01-01 张夫道 纳米级废弃塑料－淀粉混聚物生产方法及应用
NO20035745D0 (no) 2003-12-19 2003-12-19 Amersham Health As Prosess
US9468607B2 (en) * 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
US8445021B2 (en) * 2008-04-04 2013-05-21 The Regents Of The University Of California Functionalized magnetic nanoparticles and methods of use thereof
EP2310519A2 (de) 2008-08-07 2011-04-20 Bioscreen e.K. Verfahren zur epoxidation ungesättigter fettsäuren und anschliessender kopplung dieser unter verwendung einer lipase
WO2010084060A1 (en) 2009-01-21 2010-07-29 Basf Se Starch copolymers and nanoparticles thereof for drug delivery systems
CN102781965A (zh) * 2009-10-06 2012-11-14 安吉奥开米公司 用于转运治疗剂的组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1709935A (zh) * 2005-06-17 2005-12-21 天津大学 淀粉接枝聚丙烯酰胺及其衍生物反相乳液的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
pH-sensitive starch hydrogels via free radical graft copolymerization,synthesis and properties;Mohammad Reza Saboktakin et al.;《Carbohydrate Polymers》;20090211;第77卷;第634-638页 *

Also Published As

Publication number Publication date
EP2820070B1 (en) 2023-07-26
CA2865925C (en) 2021-06-01
JP2015512978A (ja) 2015-04-30
EP2820070A4 (en) 2016-03-09
US20150132384A1 (en) 2015-05-14
EP2820070A1 (en) 2015-01-07
JP6152391B2 (ja) 2017-06-21
US10233277B2 (en) 2019-03-19
CN104470975A (zh) 2015-03-25
US20190233567A1 (en) 2019-08-01
CA2865925A1 (en) 2013-09-06
US11155664B2 (en) 2021-10-26
SG11201405407WA (en) 2014-10-30
WO2013127004A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
CN104470975B (zh) 可用于治疗诊断学的聚合纳米颗粒
Li et al. Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics
Prabaharan et al. Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn® H40, poly (l-lactide) and poly (ethylene glycol) for tumor-targeted drug delivery
Sun et al. Gadolinium-loaded poly (N-vinylcaprolactam) nanogels: synthesis, characterization, and application for enhanced tumor MR imaging
Sun et al. Macrophages-targeting mannosylated nanoparticles based on inulin for the treatment of inflammatory bowel disease (IBD)
Prabaharan Chitosan-based nanoparticles for tumor-targeted drug delivery
Shen et al. Dendrimer-based organic/inorganic hybrid nanoparticles in biomedical applications
Hwang et al. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles
US9216220B2 (en) Compositions and methods for thermo-sensitive nanoparticles and magnetic nanoparticles
Díaz-López et al. The performance of PEGylated nanocapsules of perfluorooctyl bromide as an ultrasound contrast agent
Jain et al. Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice
Yan et al. Recent advances in multifunctional magnetic nanoparticles and applications to biomedical diagnosis and treatment
US9901616B2 (en) Apoptosis-targeting nanoparticles
Zhuang et al. Laponite-polyethylenimine based theranostic nanoplatform for tumor-targeting CT imaging and chemotherapy
Tran et al. Design of iron oxide nanoparticles decorated oleic acid and bovine serum albumin for drug delivery
Taghizadeh et al. Cross-linked chitosan in nano and bead scales as drug carriers for betamethasone and tetracycline
Srikar et al. Polymeric nanoparticles for molecular imaging
Pei et al. Design of Janus-like PMMA-PEG-FA grafted fluorescent carbon dots and their nanoassemblies for leakage-free tumor theranostic application
Song et al. Core–shell tecto dendrimers enable enhanced tumor MR imaging through an amplified EPR effect
Huang et al. Design and application of dextran carrier
Xiao et al. Superparamagnetic iron oxide nanoparticles stabilized with multidentate block copolymers for optimal vascular contrast in T 1-weighted magnetic resonance imaging
Shalviri et al. Multifunctional terpolymeric MRI contrast agent with superior signal enhancement in blood and tumor
Deka et al. Acidic pH-responsive nanogels as smart cargo systems for the simultaneous loading and release of short oligonucleotides and magnetic nanoparticles
Tao et al. Fe3O4 Nanoparticles Embedded in Pectin–Doxorubicin Composites as pH-Responsive Nanoplatforms for Tumor Diagnosis and Therapy by T 1-Weighted Magnetic Imaging
Laha et al. Design of core-shell stearyl pullulan nanostructures for drug delivery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant